Kyorin Pharmaceutical Co., Ltd.
Basic information
- Head office
- 〒100-0004 Tokyo, Chiyoda-ku, Otemachi 1-3-7, Nihon Keizai Shimbun Tokyo Head Office Building
- Chief executive
- Yutaka Ogiwara
- Capital
- 700,000,000 (7 100 million)
- Employees (non-consolidated)
- 1,330 people
- Employees (consolidated)
- Start date
- 1923-01-01
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
Network
History
Founded in 1923 as Toyo Shinyaku Sha, the predecessor of Kyorin Pharmaceutical, and began manufacturing and selling injections.![]()
In 1923 (Taisho 12), amid the aftermath of the Great Kanto Earthquake, Hiroshi Ogiwara established Toyo Shin Yakusha, the predecessor of Kyorin Pharmaceutical, in Arai-juku, Omori Ward, Tokyo, starting the company.![]()
Renamed Kyorin Chemical Research Institute to Kyorin Pharmaceutical Co., Ltd., and spun off the sales division to establish Kyorin Yakuhin Co., Ltd.![]()
Participated in capital with Nissin Pharmaceutical Co., Ltd. (renamed Nissin Kyorin Pharmaceutical Co., Ltd.)![]()
Consolidation of the drug discovery research institute (former Central Research Institute) and development research institute (former Research Center) and establishment of Kyorin Pharmaceutical Watrasu Drug Discovery Center![]()
Launch of the bronchial asthma and allergic rhinitis treatment drug "Montelukast Tablets 10mg/5mg 'KM'"![]()
Kyorin Pharmaceutical Co., Ltd. acquires shares of Jatus Co., Ltd., and merges through absorption (entry into diagnostic business)![]()
On June 16, 1931 (Showa 6), Kyorin Chemical Research Institute was established. It was designated as the founding (anniversary) day of our group, as it was the first time the name "Kyorin" was used.![]()
Kyorin Chemical Laboratory was renamed KYORIN Pharmaceutical Co., Ltd., and Kyorin Yakuhin Co., Ltd. was organized as an independent marketing division.![]()
In 1940 (Showa 15), Kyorin Chemical Research Institute was renamed Kyorin Pharmaceutical. Also, in the same year, Kyorin Yakuhin was established to handle sales.![]()
In 1947 (Showa 22), as the country began to recover, the Okaya Factory was opened in Okaya City, Nagano Prefecture. It operated as the main factory until 2016 (Heisei 28).![]()
In the 1960s, established a system for new drug research and development, and has contributed to people's health through research, development, production, and sales of new drugs to this day.![]()
In 1962 (Showa 37), Kyorin Chemical Research Institute was established in Ukima, Kita-ku, Tokyo, for new drug development. An organizational system was built.![]()
In 1965 (Showa 40), the headquarters was relocated to Kanda Surugadai, Chiyoda-ku, Tokyo. The headquarters building was completed.![]()
In 1967 (Showa 42), Noki Factory was opened, and production facilities were modernized to cope with increased production. It operated as a main factory from 1967 (Showa 42) to 2006 (Heisei 18).![]()
In 1977 (Showa 52), in response to the demands of the times, the Central Research Institute was established in Noki Town, Shimotsuga District, Tochigi Prefecture, to enhance the development of original new drugs. This eventually led to the development of the long-awaited new drug, Norfloxacin (Baxdilar).![]()
In 1980 (Showa 55), Norfloxacin was introduced to Merck & Co. in the United States. The company also contracted with several European pharmaceutical companies, and the drug was launched in over 130 countries and regions worldwide, which demonstrated the company's drug discovery capabilities globally.![]()
KYORIN Pharmaceutical Co., Ltd. and Kyorin Yakuhin Co., Ltd. were merged, and the new KYORIN Pharmaceutical Co., Ltd. was founded.![]()
In 1992 (Heisei 4), to consolidate management resources and strengthen the corporate structure, Kyorin Pharmaceutical and Kyorin Yakuhin merged. The new company, Kyorin Pharmaceutical Co., Ltd., which has functions from research and development to production and sales, was launched.![]()
In 1995 (Heisei 7), to achieve further stable production, stable supply, and productivity improvement, the company established the Noshiro Factory in Noshiro City, Akita Prefecture, and began operations as a new production base.![]()
A joint venture, Nisshin KYORIN Pharmaceutical Co., Ltd., was established with Kyorin’s capital participation.![]()
In 1996 (Heisei 8), aiming to strengthen the pharmaceutical business for further growth and development, the company participated in capital with Nissin Pharmaceutical Co., Ltd. and started business activities as Nissin Kyorin Pharmaceutical Co., Ltd. It merged with Kyorin Pharmaceutical in 2008 (Heisei 20).![]()
In 1996 (Heisei 8), to improve development research functions (synthesis research, safety technology, synthesis technology, formulation technology), a research center was established in Nogi Town, Tochigi Prefecture, to enhance research efficiency.![]()
In 1996 (Heisei 8), the company introduced Gatifloxacin, a new quinolone antibacterial agent, to BMS in the United States. In 2000 (Heisei 12), it introduced Gatifloxacin eye drops to Allergan in the United States.![]()
In 1998 (Heisei 10), the company inherited the business of sterilizing disinfectants for baby bottles and nipples, Milton, from P&G Group in Japan, expanding its infectious disease-related business from treatment to prevention, and strengthening the over-the-counter drug business.![]()
In April 1999 (Heisei 11), the company was listed on the Second Section of the Tokyo Stock Exchange, and was transferred to the First Section the following year, aiming to increase social standing, expand funding options, and continue investing in R&D and new business fields.![]()
In 2004 (Heisei 16), to acquire new drug discovery technology (proteomics), the company made ActivX, a biotech venture, a subsidiary to streamline and accelerate the exploration of candidate compounds. It was closed in 2023 (Reiwa 5).![]()
The stock of Toyo Pharma Co., Ltd. (present KYORIN Rimedio Co., Ltd.) was acquired, making it into a subsidiary company.![]()
In 2005 (Heisei 17), the company acquired Toyo Pharma Co., Ltd. (now Kyorin Remedio Co., Ltd.) and entered the generic drug business, working on building new businesses.![]()
The Kyorin Group shifts to a holding company structure through a share exchange with KYORIN Co., Ltd.![]()
In 2006 (Heisei 18), aiming to realize a new corporate image of a trust-based, globally-oriented drug discovery business, the company transitioned to a holding company structure and changed its name to Kyorin Corporation. In 2010 (Heisei 22), it changed its name to Kyorin Pharmaceutical Holdings, Inc., to improve recognition.![]()
Acquisition (conversion into subsidiary) of the Shiga Plant of MSD K.K. and established KYORIN Pharmaceutical Facilities Co., Ltd.![]()
In 2012 (Heisei 24), the company acquired MSD Shiga Factory to further improve production technology and capacity, establishing a new production system.![]()
Establishment of the WATARASE Research Center of KYORIN Pharmaceutical Co., Ltd. through consolidation of the Drug Discovery Center and the R&D Center.![]()
In 2015 (Heisei 27), the company consolidated its domestic research and development bases, previously dispersed across two locations, into the Watara Pharmaceutical Center on the site of the Nogi Factory in Nogi Town, Tochigi Prefecture, to enhance efficiency and collaboration.![]()
Montelukast tablets 10mg, 5mg「KM」, the leukotriene receptor antagonist and bronchial asthma treatment medicine, was launched.![]()
In 2017 (Heisei 29), to strengthen the development of generic drug formulations and increase attractive in-house developed products, the company established the Takaoka Formulation Research Institute in Takaoka City, Toyama Prefecture, focusing on solid and liquid formulations.![]()
In 2017 (Heisei 29), the company acquired all shares of Jatas Inc., established to industrialize the technology developed by the National Institute of Advanced Industrial Science and Technology, and launched the ultra-fast gene quantification device GeneSoC, which has been used for COVID-19 diagnosis.![]()
New manufacturing subsidiary, KYORIN Pharmaceutical Group Facilities Co., Ltd. (head office: Tokyo), commences operations.![]()
In 2018 (Heisei 30), the company absorbed and succeeded the Noshiro Factory and Kyorin Remedio's manufacturing headquarters into a new manufacturing subsidiary, and merged with the Kyorin Pharmaceutical Group Factory in Koka, Shiga Prefecture, to optimize group production and build a competitive manufacturing system that supplies high-quality products stably and at low cost.![]()
Lasvic Intravenous Drip Infusion Kit 150mg, an injectable new quinolone antibacterial agent, was launched.![]()
Lyfnua® Tablets 45mg, a selective P2X3 receptor antagonist for refractory chronic cough, was launched.![]()
In 2022 (Reiwa 4), the company reorganized from four market segments into three, listed on the Prime Market, and focused on meeting standards for performance, stock liquidity, corporate governance, and sustainability issues.![]()
KYORIN Holdings, Inc. changed its trade name to KYORIN Pharmaceutical Co., Ltd. through absorption type merger of KYORIN Pharmaceutical Co., Ltd.![]()
News
Kyorin Pharmaceutical Signs Exclusive Distribution Agreement for DAYBUE STIX in Japan
Kyorin Pharmaceutical Co., Ltd. has entered into an exclusive distribution agreement with Acadia Pharmaceuticals Inc. for the treatment of Rett syndrome in Japan, covering the drug DAYBUE STIX (generic name: Trofinetide). Under the agreement, the company will receive a one-time payment of 30 million U.S. dollars and will be entitled to up to 45 million U.S. dollars in milestone payments based on drug pricing inclusion and sales achievement.
Kyorin Pharmaceutical Receives Level 2 Eruboshi Certification
Kyorin Pharmaceutical received Level 2 Eruboshi Certification from the Ministry of Health, Labour and Welfare in recognition of its efforts to promote women's advancement. It meets the standards in four areas: recruitment, continued employment, working hours and other aspects of work arrangements, and diverse career paths. The company is advancing training and improving its systems, with the aim of having women make up at least 15% of managers by fiscal 2029.
Kyorin Pharmaceutical Begins Selling Vibegron for Overactive Bladder in Taiwan
Kyorin Pharmaceutical Co., Ltd. began selling vibegron, a treatment for overactive bladder, in Taiwan through a subsidiary of Marubeni Pharmaceuticals. The medicine is a once-daily oral beta-3 adrenergic receptor agonist that improves symptoms such as urinary urgency and frequent urination.
Public records
National Tax Agency basic information8010001096491
- Trade name
- 杏林製薬株式会社
- Trade name (kana)
- キョウリンセイヤク
- Name in English
- Corporation type
- 301
- Address
- 〒100-0004 東京都千代田区大手町1丁目3番7号
- Postal code
- 1000004
- Prefecture code
- 13
- City code
- 101
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2024-05-13
- Change date
- 2024-05-07
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 12
- Correction type
- 0
- Trade name image ID
- Address image ID
- Sequence number
- 2316175
METI gBizINFO8010001096491
- Corporate number
- 8010001096491
- Trade name
- 杏林製薬株式会社
- Trade name (kana)
- キョウリンセイヤク
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 東京都千代田区大手町1丁目3番7号
- Postal code
- 1000004
- Prefecture
- 東京都
- Prefecture code
- 13
- City or district
- 千代田区
- City code
- 101
- Street address
- 大手町1丁目3番7号
- Organisation type
- 301
- Processing type
- 12
- Correction type
- 0
- Status
- Representative
- 代表取締役社長 荻原 豊
- Capital
- 700000000
- Employees
- 1322
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2024-05-13
- Key information
- 8010001096491